Palmoplantar WartsNCT07881198
Liquid Nitrogen Cryotherapy Versus CO₂ Laser for Palmoplantar Warts
A study testing Liquid Nitrogen Cryotherapy and Carbon Dioxide (CO₂) Laser Therapy in people with Palmoplantar Warts, run by Bkahtawar Amin Medical and Dental College Multan at 1 site in Pakistan.
Trial summary
This randomized clinical trial will compare the effectiveness of liquid nitrogen cryotherapy and carbon dioxide (CO₂) laser therapy for treating palmoplantar warts, which are human papillomavirus-related skin growths occurring on the palms and soles. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Palmoplantar Warts
- What is being tested?
- Liquid Nitrogen Cryotherapy and Carbon Dioxide (CO₂) Laser Therapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 88 participants
- Where
- 1 sitePakistan
- Study dates
- 4 Jun 2026to 3 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Clinically diagnosed palmoplantar warts
Who cannot join
- Diabetes mellitus
- Peripheral neuropathies
- HIV
- Taking treatment (topical or laser) in last 8 weeks.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
Bkahtawar Amin Medical and Dental College Multan
Multan, Punjab Province, 60000
Warisha A Principal Investigator, MBBS, +92 333 6050539, warisha.azim96@gmail.com
Muhammad F Associate Professor, FCPS, +92 321 6833118, drfarooq05@yahoo.com
About this study
Official title: Comparison of Efficacy of Liquid Nitrogen Cryotherapy Versus CO2 Laser in Patients With Palmoplantar Warts
This randomized clinical trial will compare the effectiveness of liquid nitrogen cryotherapy and carbon dioxide (CO₂) laser therapy for treating palmoplantar warts, which are human papillomavirus-related skin growths occurring on the palms and soles.
The main question the study aims to answer is:
Read more
- Does CO₂ laser therapy achieve complete wart clearance more frequently than liquid nitrogen cryotherapy after 12 weeks of treatment?
The study will include 88 adults aged 18-50 years with palmoplantar warts. Participants will be randomly assigned to one of two treatment groups:
- Group A: Liquid nitrogen cryotherapy at -196°C, using two freeze-thaw cycles once weekly for up to 8 weeks.
- Group B: CO₂ laser therapy administered weekly for up to 8 weeks.
Participants will be assessed at week 12 after treatment initiation by a consultant dermatologist who will not know which treatment they received. Treatment response will be classified as complete clearance (no remaining warts), partial response (fewer warts than at baseline), or no response (the same or an increased number of warts). The researchers will compare the proportion of participants achieving complete wart clearance between the two groups. Adverse effects, including blistering, ulceration, and infection, will also be recorded during treatment.
- Conditions
- Palmoplantar Warts
- Being tested
- Liquid Nitrogen Cryotherapy, Carbon Dioxide (CO₂) Laser Therapy
- Keywords
- Palmoplantar Warts, Plantar Warts, Palmar Warts, Cryotherapy, Liquid Nitrogen, Carbon Dioxide Laser, CO₂ Laser Therapy, Human Papillomavirus, Wart Clearance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Liquid Nitrogen CryotherapyProcedure or surgery
Participants will be administered using two freeze-thaw cycles once weekly for a maximum of 8 weeks to treat palmoplantar warts.
Carbon Dioxide (CO₂) Laser TherapyProcedure or surgery
Participants will be administered once weekly for a maximum of 8 weeks to treat palmoplantar warts.
| Study group | Role | What they receive |
|---|---|---|
| Liquid Nitrogen Cryotherapy | Active comparator | Participants will receive liquid nitrogen cryotherapy at -196°C Receives: Procedure: Liquid Nitrogen Cryotherapy |
| CO₂ Laser Therapy | Experimental | Participants will receive carbon dioxide (CO₂) laser therapy Receives: Procedure: Carbon Dioxide (CO₂) Laser Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment Efficacy
Proportion of participants achieving complete clearance of palmoplantar warts, defined as the absence of any wart lesions at the 12-week assessment compared with baseline.
Measured: From enrollment through the final assessment at 12-weeks (including 8 weeks of treatment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2026
- Study start4 Jun 2026
- Primary completion3 Dec 2026 (estimated)
- Study completion3 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Palmoplantar WartsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bkahtawar Amin Medical and Dental College Multan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Warisha Azam Khan, Bkahtawar Amin Medical and Dental College Multan
- Investigators
- Muhammad F Associate Professor, FCPS, Study chair, Bkahtawar Amin Medical and Dental College Multan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07881198
- Sponsor's protocol ID
- U1111-1348-1366
- Status last verified
- Oct 2026
- First submitted
- 12 Oct 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Efficacy of Liquid Nitrogen Cryotherapy Versus CO2 Laser in Patients With Palmoplantar Warts
- ClinicalTrials.gov ID
- NCT07881198
- Acronym / sponsor ID
- U1111-1348-1366
- Conditions
- Palmoplantar Warts
- Keywords
- Palmoplantar Warts, Plantar Warts, Palmar Warts, Cryotherapy, Liquid Nitrogen, Carbon Dioxide Laser, CO₂ Laser Therapy, Human Papillomavirus
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 88 participants (estimated)
- Lead sponsor
- Bkahtawar Amin Medical and Dental College MultanUniversity, hospital or other
- Study start
- 4 Jun 2026 (actual)
- Primary completion
- 3 Dec 2026 (estimated)
- Study completion
- 3 Dec 2026 (estimated)
- First posted
- 19 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized clinical trial will compare the effectiveness of liquid nitrogen cryotherapy and carbon dioxide (CO₂) laser therapy for treating palmoplantar warts, which are human papillomavirus-related skin growths occurring on the palms and soles.
The main question the study aims to answer is:
- Does CO₂ laser therapy achieve complete wart clearance more frequently than liquid nitrogen cryotherapy after 12 weeks of treatment?
The study will include 88 adults aged 18-50 years with palmoplantar warts. Participants will be randomly assigned to one of two treatment groups:
- Group A: Liquid nitrogen cryotherapy at -196°C, using two freeze-thaw cycles once weekly for up to 8 weeks.
- Group B: CO₂ laser therapy administered weekly for up to 8 weeks.
Participants will be assessed at week 12 after treatment initiation by a consultant dermatologist who will not know which treatment they received. Treatment response will be classified as complete clearance (no remaining warts), partial response (fewer warts than at baseline), or no response (the same or an increased number of warts). The researchers will compare the proportion of participants achieving complete wart clearance between the two groups. Adverse effects, including blistering, ulceration, and infection, will also be recorded during treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Liquid Nitrogen Cryotherapy | Active comparator | Procedure: Liquid Nitrogen CryotherapyParticipants will receive liquid nitrogen cryotherapy at -196°C |
| CO₂ Laser Therapy | Experimental | Procedure: Carbon Dioxide (CO₂) Laser TherapyParticipants will receive carbon dioxide (CO₂) laser therapy |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Clinically diagnosed palmoplantar warts
Key exclusion criteria (4 listed)
- Diabetes mellitus
- Peripheral neuropathies
- HIV
- Taking treatment (topical or laser) in last 8 weeks.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Liquid Nitrogen CryotherapyParticipants will be administered using two freeze-thaw cycles once weekly for a maximum of 8 weeks to treat palmoplantar warts. | Procedure or surgery | Liquid Nitrogen Cryotherapy |
| Carbon Dioxide (CO₂) Laser TherapyParticipants will be administered once weekly for a maximum of 8 weeks to treat palmoplantar warts. | Procedure or surgery | CO₂ Laser Therapy |
Primary outcome
Treatment Efficacy
Time frame: From enrollment through the final assessment at 12-weeks (including 8 weeks of treatment)
Proportion of participants achieving complete clearance of palmoplantar warts, defined as the absence of any wart lesions at the 12-week assessment compared with baseline.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Palmoplantar Warts
Recruiting
Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart
Common Warts
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Muhammad F Associate Professor, FCPS study chair
Bkahtawar Amin Medical and Dental College Multan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Liquid Nitrogen Cryotherapy and Carbon Dioxide (CO₂) Laser Therapy in people with Palmoplantar Warts, run by Bkahtawar Amin Medical and Dental College Multan at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Warisha A Principal Investigator, MBBS (+92 333 6050539, warisha.azim96@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment Efficacy (time frame: From enrollment through the final assessment at 12-weeks (including 8 weeks of treatment)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.